CervoMed granted Innovation Passport for neflamapimod in UK

5 August 2026

Boston, USA-based clinical-stage biotech CervoMed (Nasdaq; CRVO) shares jumped 7.7% to $2.80 yesterday, after it announced that its investigational drug candidate, neflamapimod, has received an Innovation Passport designation to enter the UK’s Innovative Medicines and Health Products Regulatory Agency (MHRA) Accelerated Access Pathway (ILAP) for the development of neflamapimod in dementia with Lewy bodies (DLB).

The ILAP program is designed to expedite the time to market and improve patient access to innovative new medicines in the UK that address significant unmet clinical needs. Neflamapimod was selected for the ILAP through a joint consensus, recognized for its potential as an innovative therapy for DLB, a condition with a high unmet need and the demonstrated potential to offer a major therapeutic advantage.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK